Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy

Loading news article.

Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy | WAPE

Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy

Article summary

Related companies

Comments —